

U.S. TRADEMARK OFFICE
DEC 06 2004

Sheet 1 of 4

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	04843/117002
				Serial No.	10/740,075
				Applicant	Renshaw et al.
				Filing Date	December 17, 2003
				Group Art Unit	1623
				IDS Filed	December 2, 2004
(37 C.F.R. § 1.98(b))					

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
<i>JL</i>	A1 4,027,017	05/31/1977	Hata et al.	_____	_____	
<i>JL</i>	A6 4,048,316	09/13/1977	Penn	_____	_____	
<i>JL</i>	A3 4,115,576	09/19/1978	Penn	_____	_____	
<i>JL</i>	A4 4,704,361	11/03/1987	Miccoli et al.	_____	_____	
<i>JL</i>	A5 5,278,176	01/11/1994	Lin	_____	_____	
<i>JL</i>	A6 5,409,946	04/25/1995	Garvey et al.	_____	_____	
<i>JL</i>	A7 5,472,958	12/05/1995	Gunn, Jr. et al.	_____	_____	
<i>JL</i>	A8 5,691,320	11/25/1997	von Borstel et al.	_____	_____	
<i>JL</i>	A9 5,919,789	07/06/1999	Dyke et al.	_____	_____	
<i>JL</i>	Dupl. 3,950,090	09/26/1999	Renshaw et al.	_____	_____	
<i>JL</i>	A10 6,103,703	08/15/2000	Renshaw et al.	_____	_____	
<i>JL</i>	A11 6,153,653	11/28/2000	Shashoua	_____	_____	
<i>JL</i>	A12 2002/019364	02/14/2002	Renshaw	_____	_____	
<i>JL</i>	A13 2003/220291	11/27/2003	Renshaw	_____	_____	
<i>JL</i>	A14 2004/176316	09/09/2004	Renshaw et al.	_____	_____	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
<i>JL</i>	B1 JP 08-183737	07/16/1996	Japan	_____	_____	
<i>JL</i>	B2 0 188647 A1	07/30/1986	EPO	_____	_____	
<i>JL</i>	B3 WO 00/06174	02/10/2000	WIPO	_____	_____	

DUPL. - Duplicate citation: see PTO-892 for citation.

EXAMINER L. E. Crane	DATE CONSIDERED 03/23/2006
----------------------	----------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	04843/117002
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/740,075
				Applicant	Renshaw et al.
				Filing Date	December 17, 2003
				Group Art Unit	1623
(37 C.F.R. § 1.98(b))				IDS Filed	December 2, 2004

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
<i>PLC</i>	C1	Agnoli et al., "Efficacy of CDPcholine in Chronic Cerebral Vascular Diseases (CCVD)," <i>Novel Biochemical, Pharmacological and Clinical Aspects of Cytidinephosphocholine</i> Elsevier 305-315 (1985).			
	C2	Alvarez et al., "Double-Blind Placebo-Controlled Study with Citicoline in APOE Genotyped Alzheimer's Disease Patients. Effects on Cognitive Performance, Brain Bioelectrical Activity and Cerebral Perfusion," <i>Methods Find Exp. Clin. Pharmacol.</i> (Abstract) 21:633-644 (1999).			
	C3	Babb et al., "Differential Effect of CDP-choline on Brain Cytosolic Choline Levels in Younger and Older Subjects as Measured by Proton Magnetic Resonance Spectroscopy," <i>Psychopharmacology</i> 127:88-94 (1996).			
	C4	Boudouresques et al., "Therapeutic Conduct in Light of a Cerebral Vascular Accident and the Use of CDP-Choline," <i>International Symposium: Brain Suffering and Precursors of Phospholipids</i> pp. 1-13 (1980).			
	C5	Brown et al., "CNS Complications of Cocaine Abuse: Prevalence, Pathophysiology, and Neuroradiology," <i>Am. J. Roentgenol.</i> 159:137-147 (1992).			
	C6	Centrone et al., "Use of Citicoline in High Dosages in Acute Cerebrovascular Disease," <i>Minerva Med.</i> (English Abstract) 77:371-373 (1986).			
	C7	Chang et al., "Neurochemical Alterations in Asymptomatic Abstinent Cocaine Users: A Proton Magnetic Resonance Spectroscopy Study," <i>Biol. Psychiatry</i> 42:1105-1114 (1997).			
	C8	Christensen et al., "Abnormal Cerebral Metabolism in Polydrug Abusers During Early Withdrawal: A ³¹ P MR Spectroscopy Study," <i>Magn. Reson. Med.</i> 35:658-663 (1996).			
	C9	Citicoline Sodium (CDP-Choline), <i>Investigator's Brochure</i> , Revised: April 1994 by Interneuron Pharmaceuticals, Inc.			
	C10	Cohen et al., "Decreased Brain Choline Uptake in Older Adults, An in vivo Proton Magnetic Resonance Spectroscopy Study" <i>JAMA</i> 274:902-907 (1995).			
	C11	English et al., "Elevated Frontal Lobe Cytosolic Choline Levels in Minimal or Mild AIDS Dementia Complex Patients: A Proton Magnetic Resonance Spectroscopy Study," <i>Biol. Psychiatry</i> 41:500-502 (1997).			
	C12	Fioravanti et al., "Cytidinephosphocholine (CDP Choline) for Cognitive and Behavioural Disturbances Associated with Chronic Cerebral Disorders in the Elderly," <i>Cochrane Database Systems</i> (Abstract) 4:CD000269 (2000).			
	C13	Gallai et al., "Study of the P300 and Cerebral Maps in Subjects with Multi-Infarct Dementia Treated with Cytidine," <i>Psychopharmacology</i> 103:1-5 (1991).			
	C14	Galletti et al., "Biochemical Rationale for the Use of CDPcholine in Traumatic Brain Injury: Pharmacokinetics of the Orally Administered Drug," <i>J. Neurol. Sci.</i> 103:S19-S25 (1991).			
<i>PLC</i>	C15	Hoff et al., "Effects of Crack Cocaine on Neurocognitive Function," <i>Psychiatry Res.</i> 60:167-176 (1996).			
EXAMINER L. E. Crane <i>L.E.C.</i>			DATE CONSIDERED 03/23/2006		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No.	04843/117002 10/740,075
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Renshaw et al.
		Filing Date	December 17, 2003
		Group Art Unit	1623
(37 C.F.R. § 1.98(b))		IDS Filed	December 2, 2004

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
C16	Jacobs et al., "Cocaine Abuse: Neurovascular Complications," <i>Radiology</i> 170:223-227 (1989).
C17	Kaufman et al., "Cocaine-Induced Cerebral Vasoconstriction Detected in Humans with Magnetic Resonance Angiography," <i>JAMA</i> 279:376-380 (1998).
C18	Kreek, "Opiate and Cocaine Addictions: Challenge for Pharmacotherapies," <i>Pharmacol. Biochem. Behav.</i> 57:551-569 (1997).
C19	Levin et al., "Improved Regional Cerebral Blood Flow in Chronic Cocaine Polydrug Users Treated with Buprenorphine," <i>J. Nucl. Med.</i> 36:1211-1215 (1995).
C20	London et al., "Cerebral Glucose Utilization in Human Heroin Addicts: Case Reports from a Positron Emission Tomographic Study," <i>Res. Commun. Subst. Abuse</i> 10:141-144 (1989).
C21	Lukacska et al., "Modulation of the Vasoconstrictor Response to Adrenergic Stimulation by Nucleosides and Nucleotides," <i>J. Pharmacol. Exp. Ther.</i> 222:344-349 (1982).
C22	Lukas et al., "Effects of Short-Term Citicoline Treatment on Acute Cocaine Intoxication and Cardiovascular Effects," <i>Psychopharmacology</i> 157:163-167 (2001).
C23	Maas et al., "Functional Magnetic Resonance Imaging of Human Brain Activation During Cue-Induced Cocaine Craving," <i>Am. J. Psychiatry</i> 155:124-126 (1998).
C24	Malec et al., "Influence of Adenosinergic Drugs on Ethanol Withdrawal Syndrome in Rats," <i>Pol. J. Pharmacol.</i> 48:583-588 (1996). (Abstract only).
C25	McCance, "Overview of Potential Treatment Medications for Cocaine Dependence," <i>NIDA Res. Monogr.</i> 175:36-72 (1997)..
C26	Moglia et al., "Citicoline in Patients with Chronic Cerebrovascular Diseases (CCVD): Quantitative EEG Study," <i>Curr. Ther. Res.</i> 36:309-313 (1984).
C27	Monticone et al., "On the Therapeutic Use of Nucleosides, Cytidine and Uridine, in some Neurological Diseases," <i>Minerva Med.</i> 57:4348-4352 (1966). (plus PubMed Abstract).
C28	O'Rourke et al., "Effect of Chronic Cocaine Exposure on Carotid Artery Reactivity in Neonatal Rabbits," <i>Life Sci.</i> 59:119-130 (1996).
C29	Page et al., "Developmental Disorder Associated with Increased Cellular Nucleotidase Activity," <i>Proc. Natl. Acad. Sci. USA</i> 94:11601-11606 (1997).
C30	Peterson et al., "Neurovascular Complications of Cocaine Abuse," <i>J. Neuropsychiatry Clin. Neurosci.</i> 3:143-149 (1991).
C31	Radulovacki et al., "Adenosine Analogs and Sleep in Rats," <i>J. Pharmacol. Exp. Ther.</i> 228:268-274 (1984).

EXAMINER L. E. Crane	DATE CONSIDERED	03/23/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		


SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04843/117002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/740,075
(37 C.F.R. § 1.98(b))		Applicant	Renshaw et al.
		Filing Date	December 17, 2003
		Group Art Unit	1623
		IDS Filed	December 2, 2004

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
	C32	Renshaw et al., "Short-term Treatment with Citicoline (CDP-choline) Attenuates some Measures of Craving in Cocaine-Dependent Subjects: A Preliminary Report," <i>Psychopharmacology</i> 142:132-138 (1999).	
	C33	Saligaut et al., "Circling Behaviour in Rats with Unilateral Lesions of the Nigrostriatum Induced by 6-Hydroxydopamine: Changes Induced by Oral Administration of Cytidine-5'-Diphosphocholine," <i>Neuropharmacology</i> 26:1315-1319 (1987).	
	C34	Salvadorini et al., "Clinical Evaluation of CDP-choline (NICHOLIN®): Efficacy as Antidepressant Treatment," <i>Curr. Ther. Res.</i> 18:513-520 (1975).	
	C35	Satoh et al., "Involvement of Adenosine A _{2A} Receptor in Sleep Promotion," <i>Eur. J. Pharmacol.</i> 351:155-162 (1998).	
	C36	Scammell et al., "An Adenosine A _{2A} Agonist Increases Sleep and Induces Fos in Ventrolateral Preoptic Neurons," <i>Neuroscience</i> . 107:653-663 (2001).	
	C37	Secades et al., "CDP-Choline: Pharmacological and Clinical Review," <i>Meth. Find. Exp. Clin. Pharmacol.</i> 17(Suppl. B):1-54 (1995).	
	C38	Self, et al., "Opposite Modulation of Cocaine-Seeking Behavior by D ₁ - and D ₂ -like Dopamine Receptor Agonists," <i>Science</i> 271:1586-1589 (1996).	
	C39	Shekim et al., "S-Adenosyl-L-Methionine (SAM) in Adults with ADHD, RS: Preliminary Results from an Open Trial," <i>Psychopharmacol. Bull.</i> 26:249-253 (1990).	
	C40	Sholar et al., "Concurrent Pharmacokinetic Analysis of Plasma Cocaine and Adrenocorticotropic Hormone in Men," <i>J. Clin. Endocrinol. Metab.</i> 83:966-968 (1998).	
	C41	Tazaki et al., "Treatment of Acute Cerebral Infarction with a Choline Precursor in a Multicenter Double-Blind Placebo-Controlled Study," <i>Stroke</i> 19:211-216 (1988).	
	C42	Teoh et al., "Acute Interactions of Buprenorphine with Intravenous Cocaine and Morphine: An Investigational New Drug Phase I Safety Evaluation," <i>J. Clin. Psychopharmacol.</i> 13:87-99 (1993).	
	C43	Tomos et al., "Effect of Oral CDP-Choline on Experimental Withdrawal Syndrome," <i>Arzneim.-Forsch./Drug Res.</i> 33:1018-1021 (1983).	
	C44	Warner et al., "Pharmacotherapy for Opioid and Cocaine Abuse," <i>Med. Clin. North Am.</i> 81:909-925 (1997).	
	C45	Weiss, "Metabolism and Actions of CDP-Choline as an Endogenous Compound and Administered Exogenously as Citicoline," <i>Life Sci.</i> 58:637-660 (1995).	
	C46	Wurtman et al., "Effect of Oral CDP-choline on Plasma Choline and Uridine Levels in Humans," <i>Biochem. Pharmacol.</i> 60:989-992 (2000).	

EXAMINER L. E. Crane	<i>L. E. Crane</i>	DATE CONSIDERED	03/23/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			



Sheet 1 of 1



Sheet 1 of 1

<p>U.S. SUBSTSTITUTE FORM PTO-1449 (MODIFIED)</p> <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>	<p>Attorney Docket No. 04843/117002</p> <p>Serial No. 10/740,075</p> <p>Applicant Perry F. Renshaw et al.</p> <p>Filing Date December 17, 2003</p> <p>Group Art Unit 1623</p> <p>IDS Filed June 16, 2005</p>
--	--

EXAMINER L. E. Crane <i>L. E. Crane</i>	DATE CONSIDERED 03/23/2006
---	----------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



Sheet 1 of 1

SUBSTITUTE FORM PTO-149 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04843/117002
			Serial No.	10/740,075
			Applicant	Perry F. Renshaw et al.
			Filing Date	December 17, 2003
			Group Art Unit	1623
(37 C.F.R. § 1.98(b))			IDS Filed	June 22, 2005

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
PCL A16	5,977,174	11/2/1999	Bradley et al.	_____	_____	
A17	6,277,855	08/21/2001	Yerxa	_____	_____	
MK A18	2002/0182196 A1	12/5/2002	McCleary	_____	_____	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
B4	DE 3400276 A1	7/18/1985	Germany	_____	_____	
B5	EP 0218190 A2	4/15/1987	EPO	_____	_____	
B6	EP 0218190 B1	11/29/1989	EPO	_____	_____	
B7	JP 63-208254	8/30/1988	Japan	_____	_____	
B8	WO 99/26620	6/3/1999	WIPO	_____	_____	
B9	WO 01/72288 A2	10/4/2001	WIPO	_____	_____	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

C48	Carlezon et al., "Antidepressant-Like Effects of Cytidine in the Forced Swim Test in Rats," <i>Biol. Psychiatry</i> 51:882-889 (2002).
C49	Pleul et al., "Lithium Therapy and the Turnover of Phosphatidylcholine in Human Erythrocytes," <i>Euro. J. Clin. Pharmacol.</i> 31:457-462 (1986).
C50	Stoll et al., "Choline in the Treatment of Rapid Cycling Bipolar Disorder," <i>Biol. Psychiatry</i> 40:382-388 (1996).

EXAMINER L. E. Crane <i>L. E. Crane</i>	DATE CONSIDERED 03/23/2006
---	----------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



Sheet 1 of 1

<p>SUBSTITUTE FORM PTO-1449 (MODIFIED)</p> <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>	<p>Attorney Docket No. 04843/117002</p> <p>Serial No. 10/740,075</p> <p>Applicant Perry F. Renshaw et al.</p> <p>Filing Date December 17, 2003</p> <p>Group 1623</p> <p>IDS Filed March 27, 2006</p> <p>Customer No. 21559</p>
---	---

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
He	A19	5,888,532	Mar. 30, 1999	Pritsos et al.	-----	-----

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
Re	B10	EP 0 431 758 A2	Jun. 12, 1991	EPO	-----	-----
Re	B11	WO 00/11952	Mar. 9, 2000	WIPO	-----	-----

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

EXAMINER	L. E. Crane <i>[Signature]</i>	DATE CONSIDERED	04/27/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

Form PTO-892 U.S. Department of Commerce	Serial Number 10/740,075	Group Art Unit 1623	Attachment to Paper Number 04192006	
Notice of References Cited	APPLICANT(S) Renshaw et al.			

Published U. S. Patent Applications

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate

U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate

@ Cited herein for the first time: images are available for downloading on line at <www.uspto.gov>.

Foreign Patent Documents

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS		
	---							-----	-----

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	R	Anon. (I), "Problem Sleepiness," National Institutes of Health, NIH Publication No. 97-4071, Bethesda, MD, pages 1-4 (September, 1997).††
*	S	D. B., Greenberg,†† "Clinical Dimensions of Fatigue," Primary Care Companion, <i>Journal of Clinical Psychiatry</i> , 4(3), 90-93 (2002).
*	T	Anon. (II), Search of PubMed for "cognitive function," May 16, 2005, 29 references cited on three pages.††
*	U	PCT Chapter I, Search report for PCT/US03/40450 derived from the same provisional US parent application (60/435,457) as the instant case, received by applicant January 28, 2005.††

† Month of publication data could not be determined from the copy in hand. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Copy supplied, but apparently not cited, by applicant.

EXAMINER L. E. Crane 	DATE 04/18/06	page 1 of 1 ¥:Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

10/740,075 PTO-892 Copy for [] FILE  APPLICANT [] IFW Attachmnt to P.N. 04192006